Dear Friends of TAG:

I’m thrilled to share with you the 2011 Annual Report of Treatment Action Group (TAG), whose work your support makes possible. All of us in the TAG family—board, staff, consultants, allies, and supporters like you—are deeply grateful for your support and proud of the work it enables.

In 2011, TAG continued its work engaging with researchers, advocating with policy makers, and acting to strengthen community responses to the interrelated epidemics of HIV, hepatitis C virus (HCV), and tuberculosis (TB).

We thank you for your ongoing support to end these three diseases and to ensure that all those living with them receive the information, care, and treatment they need to save their lives.

Yours truly,

Barbara Hughes
President, Board of Directors

TAG’s 2011 Research in Action Awards recipient John Benjamin Hickey, TAG’s Mark Harrington, recipient Dr. Polly Harrison, TAG board President Barbara Hughes, and recipient Dr. Robert Siliciano.
Research in Action Awards 2011

TAG’s annual Research in Action Awards (RIAA) honors activists, scientists, philanthropists, and creative artists who have made extraordinary contributions in the fight against AIDS. RIAA is a fundraiser to support TAG’s programs and provides a forum to honor heroes of the epidemic.

TAG’s 2011 Research in Action Awards event was held on Sunday, December 11, at the Midtown Loft on 5th Avenue at 29th Street. Jenna Wolfe, weekend anchor on NBC’s “Today Show,” hosted the event. The 2011 RIAA recipients were:

**John Benjamin Hickey**, who won the 2011 Tony Award for best featured actor in a play for his performance in the revival of Larry Kramer’s *The Normal Heart*. He made his Broadway debut in Terrence McNally’s *Love! Valour! Compassion!* and reprised his part in the film version. He has also appeared on Broadway in *The Crucible*, *Mary Stuart*, and the Tony Award winning revival of *Cabaret*, opposite Natasha Richardson. His film work includes Clint Eastwood’s *Flags of Our Fathers*, *The Ice Storm*, and *The Anniversary Party*. He appeared on television in *Me and My Shadows: Life with Judy Garland*, *Sex and the City*, and *The Good Wife*, among others. He is currently appearing in the third season of Showtime’s *The Big C*, playing Laura Linney’s crazy brother;

**Dr. Polly Harrison**, Founder of the Alliance for Microbicide Development, whose trail-blazing advocacy for woman-controlled prevention methods led to the discovery in 2010 of an effective topical vaginal gel which reduced HIV acquisition by 44% among sexually active women in South Africa; and

**Dr. Robert F. Siliciano**, Medical Investigator at the Howard Hughes Medical Institute and Professor of Medicine at the Johns Hopkins University School of Medicine, who made groundbreaking discoveries in HIV in the late 1990s. These discoveries demonstrated the size and location of the reservoir of latently infected CD4 T cells that present the main target for HIV cure research. Currently his lab is leading the search for new curative approaches to HIV that are safe, affordable, and can be rolled out worldwide to end the pandemic.
Contributing a TAG limited edition to RIAA 2011 was acclaimed artist and photographer Bill Jacobson, who generously donated a limited edition of 20 original framed images entitled New Year’s Day #5090 [2003], a 12”x10” archival pigment print, especially printed by the artist for TAG. Jacobson has exhibited widely throughout the United States and Europe, and his work is in major museum collections, including the Whitney Museum, the Guggenheim Museum, the Metropolitan Museum of Art, the San Francisco MoMA, the Victoria and Albert Museum, and many others. A solo exhibit, “Into the Loving Nowhere (1989 till now),” opened October 20th at the Julie Saul Gallery in New York City. Jacobson’s work was also included in the groundbreaking exhibit “Hide/Seek: Difference and Desire in American Portraiture” at the Brooklyn Museum. An overview of Jacobson’s work is available at his website: billjacobsonstudio.com.

HIV CURE CAMPAIGN

In 2011, TAG launched the Accelerating Research to Cure AIDS Project. The National Institutes of Health (NIH) committed over $70 million to three Martin Delaney Collaboratories dedicated to conducting basic and clinical research to cure HIV. To ensure that clinical trials are expedited in a safe, ethical, and community-participatory manner, in April 2011 TAG cosponsored, with amfAR, AIDS Policy Project, and Project Inform, the first international workshop on HIV cure-related clinical research issues. You can read the report of the Baltimore, MD, workshop here: http://www.treatmentactiongroup.org/cure/2011-workshop-report. Researchers, regulators, and activists agreed on a common set of priority issues to move HIV cure research forward faster. The workshop recommendations are being implemented during 2012 in a Cure Research Project bringing together the U.S. Food and Drug Administration (FDA); the NIH; academic, pharmaceutical, and biotechnology researchers; and community groups including TAG, through the Forum for Collaborative HIV Research to advance the agenda set in Baltimore last year. In June, Dr. David D. Ho of New York’s Aaron Diamond AIDS Research Center presented an update on HIV cure research at TAG’s annual Palm Donor Circle event, where the Cure campaign was launched. Later in 2011, TAG brought together 36 activists from around the country for an intensive workshop on HIV cure and aging research. The activists then visited over 100 legislators in both the Senate and the House to urge them to keep funding for the NIH, including its AIDS research programs, strong. Surprisingly, at the end of 2011, Congress voted the NIH an extra and unexpected $150 million to ensure its growth—though still at rates below inflation.

HIV PREVENTION AND TREATMENT ADVANCES

The biggest HIV research advance of 2011 was the stunning 96% reduction in HIV transmission achieved in HIV Prevention Trials Network (HPTN) study 052, which asked whether giving HIV therapy to the HIV-positive partner in a serodiscordant committed relationship at a CD4 count of 350–550 CD4 cells/mm³—which was earlier than recommended in then-current treatment guidelines—would reduce transmission of HIV to the HIV-negative partner. This dramatic benefit of earlier treatment as prevention (TasP) was complemented by data from the same study indicating that the earlier treatment benefitted the individual taking it by reducing their HIV progression by 41%. Several other studies showed that dual-HIV therapy could reduce HIV acquisition when taken by HIV-negative individuals as long as they took the therapy regularly.

These advances brought into sight for the first time the possibility of ending the HIV pandemic using current prevention and treatment approaches combined optimally in a setting of universal access [see “We CAN End the AIDS Epidemic”: http://www.treatmentactiongroup.org/policy/we-can-end-aids-epidemic].

TAG led the Coalition for HIV and Aging Research and Policy Advocacy (CHARPA), which met with officials from NIH and succeeded in persuading them to establish a new advisory committee for HIV and aging research, including scientists and activists, whose recommendations will come out in mid-2012.
2011 also saw FDA approval of a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV, the drug rilpivirine (Edurant) marketed by Janssen/Tibotec as a single pill or in a fixed-dose, once-a-day combination with Gilead’s Truvada (tenofovir/3TC) as Complera.

Despite the advances in research, TAG and our allies had to battle a bitter fiscal climate in Washington, DC, and globally to ensure that funding for U.S. and global research and treatment programs survived the austerity and budget cuts prevalent in almost all developed nations. In a turnaround late in 2011, the Obama administration committed to more ambitious HIV treatment targets globally, setting a goal of supporting HIV treatment for at least six million people around the world by the end of 2013. In the United States, thousands continued on state AIDS Drug Assistance Program (ADAP) waiting lists for HIV treatment, but the administration made halting—and inadequate—efforts to reduce the wait by helping cash-strapped states.

**HCV TREATMENT REVOLUTION UNFOLDS AS TAG FIGHTS FOR HIGH-QUALITY RESEARCH AND WIDESPREAD ACCESS**

In 2011, TAG’s Hepatitis/HIV Project Director, Tracy Swan, continued her work with activists and community groups, the FDA, the European Medicines Agency (EMA), the pharmaceutical industry, academic researchers, clinicians, and policy makers to improve the quality of, and broaden access to, HCV treatment for everyone who needs it. She coordinated the Hepatitis Community Advisory Board (HCAB), an international group of treatment activists focused on hepatitis C virus (HCV) drug development. HCAB works to ensure that clinical trials include people most in need of treatment as soon as it is safe to do so, and that these therapies are developed for people considered more difficult to treat than traditional trial participants.

Although hepatitis C can be cured, many people remain undiagnosed and untreated. In the United States, where at least five million people are living with HCV, the death rate from HCV complications surpassed HIV-related mortality five years ago. In turn, liver disease from HCV coinfection is a leading cause of death among HIV-positive people where antiretroviral therapy is available. Thanks to pressure from TAG and our allies, trials in people with HIV and HCV coinfection now begin years earlier, providing lifesaving information and access.

In 2011, the first of many changes in the standard of care for hepatitis C began. The first all-oral cure was reported from an early-stage trial. The standard of care improved with the approval of two protease inhibitors specifically made to work against HCV, but these drugs must be used with pegylated interferon (which is injected once weekly) and ribavirin—a pair of toxic drugs. Although HCV protease inhibitors increase cure rates and can shorten treatment duration, they cannot be taken with many commonly-used drugs, including certain antiretroviral agents, and they make HCV treatment more expensive, more difficult to undergo, and more complicated to deliver. Unlike HIV, where activists have fought to create a treatment delivery system that educates and supports patients and their medical providers, the infrastructure to diagnose and administer HCV treatment is inadequate, and there is a lack of experienced and willing providers. TAG’s Hepatitis/HIV project works with our allies, domestically and globally, to leverage HCV treatment advances into widespread access to a cure.

**PROGRESS AGAINST TUBERCULOSIS (TB)**

Last year saw several significant advances against tuberculosis (TB), which is the leading global killer of people with HIV. Many countries began to roll out the Cepheid GeneXpert MTB/RIF test, which can diagnose TB in two hours compared with the standard 8–12 weeks with bacterial culture, and which can also detect certain forms of drug-resistant TB. The test is a breakthrough, but its cost ($17,000 per machine and $17 per test cartridge) and technical requirements mean that it is still far from being the point-of-care diagnostic test that is the holy grail of TB diagnostics research. 2011 also saw the first study of a novel combination against TB in the TB Alliance’s NC-001 study, as well as a regulatory filing from Otsuka for conditional approval in Europe of its new TB drug, delamanid (OPC-67683), and the ground-breaking compassionate-use early access program from Janssen/Tibotec for its new TB drug, bedaquiline (TMC207), for people with advanced drug-resistant disease. TAG continued to lead global activist engagement with the TB research establishment by founding the Global TB Community Advisory Board (TB CAB), which met in November with Janssen/Tibotec, Otsuka, and the TB Alliance. TAG also met with the main funders of TB research globally in Bellagio, Italy, in March 2011 to encourage greater communication and collaboration among those supporting discovery and development of better strategies to ultimately eliminate TB.
2011 CONTRIBUTORS

$100,000 OR MORE
The Bill & Melinda Gates Foundation
Genentech Inc.
World Health Organization/Stop TB Partnership

$50,000–$99,999
Gilead Sciences Inc.
Elton John AIDS Foundation
Veterans Affairs Medical Center of Washington D.C.
VivHealthcare Company

$25,000–$49,999
JPMorgan Chase Bank N.A.
Levi Strauss Foundation
The Christy & John Mack Foundation
Newman’s Own Foundation

$10,000–$24,999
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Broadway Cares/Equity Fights AIDS
The Calamus Foundation
City of New York/New York City Council
David Carbery
Geno Foundation
Kent Richard Hofmann Foundation
Janssen Therapeutics/Tibotec Therapeutics
John M. Lloyd Foundation
Elizabeth Taylor AIDS Foundation

$5,000–$9,999
amfAR, the Foundation for AIDS Research
Richard A. & Barbara Knowles Debs/
“The Debs Foundation
M. Lee Garrison
Dr. Michael F. Giordano
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Global Health Strategies
Kevin & Neil Goetz/Screen Engine LLC
Michael K. Longacre
Robert J. McLain & Alberto Blanquel
Monte Steinman
Jon Styrker/Arcus Gift Fund
W. Kirk Wallace & Mark M. Sexton Fund of
Stonewall Community Foundation
Andrew D. Zacks Foundation

$500–$999
Troy & Mary Alexander “In Honor of the Marriage
of Bruce Schackman & Ed Sikov”
Jeffrey Arnost & Michael Field
Katherine C. & Thomas M. Ash III
Alvin H. Baum, Jr.
John Caldwell
Eli & Jolie Camhi
Scott P. Campbell
Dr. & Mrs. Charles C.J. Carpenter
Paula & Mitchell Chalfin and Megan Lewis/
Neshoma Foundation
Arianna Z. Dar/Marin Community Foundation
Edward J. Davis & Thomas D. Phillips
Stephen M. Dillon, M.D.
Dinowitz & Bove
Simon Donnan & Jonathan Adler
Senator Thomas K. Duane & Louis Webre
Sabina Fila
Harty Fleischmann Family
Steven M. Frank & Dr. Elizabeth S. Powell
Steven & Judith Gluckstein “In Honor of
Michael Palm”
Rene Gonzalez
Jacquelyn A. Grimm
Dr. Roy M. “Trip” Gulick M.D. & Tom Beckett
Mark Harrington
Kevin Jennings & Jeff Davis “In Memory of Joe
Monteleone” & “In Honor of Robert Monteleone”
Paul E. Kennedy
Dr. Charles King/Housing Works
Winston B. Layne
Kate B. Leer
Lorenzo Lopez Interiors
Dorothy Lonodun Foundation/Lionel Lamer
Matthew W. Mayer
Kenneth T. Monteiro & Leo J. Blackman
Laura Morrison
Mrla & George Morrison
David J. & Maria C. Pauldine
David A. Rimple & Paul Teixeira
Scott Robbe
David Sigal & Brad Hoyalman
Jane Silver/Irene Diamond Fund

$250–$499
Amazon.com
Thomas Approbato
Jim Aquino
Lysa M. Ashcroft “In Honor of Barbara Hughes”
Michael Beltran & Tim Ford
Karen Bronzo & Jeff Rabb
Bob Bronzo
Paul LeMar Brown “In Honor of Frank Rappa”
Prof. Richard M. Busbaum & Catherine B. Hartshorn
Denise B. Dailey
Scott Dainton
Joshua C. David & Stephen D. Hirsh “In Honor of
Robert Monteleone”
Edward Dulles & Phillip Miller
Jim Edwards
Joy Episaila
Alan E. Farley
Ruth K. Finkelstein & Elizabeth BC Craig
Melissa & Daniel Thabo Fisher
Kenneth L. Geist
Leslie Asako Gladsjo
Judith Green, Ph.D. & Carl Berg, PhD
Robert A. Guida, M.D., P.C.
Kenneth Hecht
Karen Hirdt “In Memory of Joseph Monteleone”
Drew Hodges
Jay Johnson
Nancy Kass
Martin Katz “In Honor of Monte Steinman”
Kevin Kliner & Jordan Baker-Kliner
David Levine
Francois Maisonrouge
Joseph McConnell & Erik Haagensen
Bonnie McEwen & Kathy Duncan
Elaine & Glenn W. Mealy
New Mexico Community Foundation
Austin Noto & Daniel E. Weiss/Austin Noto Plants
Donna M. Pauldine “In Memory of Jeff Palladino”
Andy & Andrea Potash
Daphne Powell & Christopher Harrington
Shirley G. Romney
Stephan Shaw & Sunita Viswanath
Samuel J. Silling
Morton S. & Margaret Garber-Steinberg “In Honor
of Janson Oster”
Antonio Strazzullo
Peter C. & Sherry Kay Venokur
Juan & Ariadne C. Villarreal
Kim D. Walter
Mark Wyn “In Honor of Larry Kramer”
Plus donations from an additional 287 contributors

In-Kind Donations
Jonathan Adler Shops
A/X Armani Exchange
David Barton Gym
Marc Berman/Club 570
Chopin Vodka Company
David Gersten & Associates
LARABAR
J.Lohr Vineyards & Wines
Museum of Modern Art
People Magazine
Sephora
the watsons
### TAG FINANCIALS 2011

**STATEMENTS OF FINANCIAL POSITION**

<table>
<thead>
<tr>
<th>Year ended December 31</th>
<th>2011</th>
<th>2010 (Restated)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,319,417</td>
<td>$1,107,256</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>1,038,191</td>
<td>1,078,031</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>5,789</td>
<td>7,517</td>
</tr>
<tr>
<td>Donated inventory</td>
<td>242,500</td>
<td>200,500</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>2,605,897</td>
<td>2,393,304</td>
</tr>
<tr>
<td>Property and equipment-net of accumulated depreciation</td>
<td>30,130</td>
<td>35,369</td>
</tr>
<tr>
<td>Security deposits</td>
<td>43,015</td>
<td>20,654</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>2,679,042</td>
<td>2,449,327</td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$23,023</td>
<td>$2,860</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>23,023</td>
<td>2,860</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>1,656,206</td>
<td>1,269,459</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>999,813</td>
<td>1,177,008</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>2,656,019</td>
<td>2,446,467</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,679,042</td>
<td>2,449,327</td>
</tr>
</tbody>
</table>

**STATEMENTS OF CASH FLOWS**

**Cash flows from operating activities**
- Increase (Decrease) in net assets | $209,552 | $(258,708)
- Adjustments to reconcile increase in net assets to net cash provided by operating activities |
  - Depreciation | 26,452 | 17,264 |
  - Donated inventory received | (70,000) | (50,000) |
  - Direct benefit to event participants | 28,000 | 22,500 |

**(Increase) Decrease in current assets**
- Contributions receivable | 39,840 | (37,935) |
- Prepaid expenses | 1,728 | 3,201 |
- Security deposits | (22,361) | – |

**(Decrease) Increase in current liabilities**
- Accounts payable and accrued expenses | 20,163 | (13,282) |

**NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES**
|                         | $233,374 | $(316,960) |

**Cash flows from investing activities**
- Purchases of property and equipment | (21,213) | (1,350) |
- Net cash used in investing activities | (21,213) | (1,350) |
- Net increase (decrease) in cash balance | 212,161 | (318,310) |

**CASH, BEGINNING OF YEAR**
|                         | 1,107,256 | 1,425,566 |

**CASH, END OF YEAR**
|                         | $1,319,417 | $1,107,256 |

**Supplementary disclosures of cash flow information**
- Donated goods and services | $110,624 | $78,937 |

**RESTATEMENT OF NET ASSETS AND PRIOR PERIOD**
- Effective January 1, 2010, TAG made adjustments to its net assets to reflect the estimated fair value of art-prints contributed in prior years, but not recorded on prior years financial statements. As a result, the balance of net assets of January 1, 2010 increased by $173,000. In addition, special event income was increased by $27,500 in the Statements of Activities of year 2010 to reflect additional donated art-prints inventory and used in special event.
## REVENUE AND SUPPORT

<table>
<thead>
<tr>
<th>Source</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>2011 Total</th>
<th>2010 Total (Restated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct mail</td>
<td>$ 28,760</td>
<td>–</td>
<td>$ 28,760</td>
<td>$ 40,808</td>
</tr>
<tr>
<td>Donations</td>
<td>25,049</td>
<td>–</td>
<td>25,049</td>
<td>20,331</td>
</tr>
<tr>
<td>Grants</td>
<td>655,893</td>
<td>1,003,713</td>
<td>1,659,606</td>
<td>1,455,351</td>
</tr>
<tr>
<td>Special event income</td>
<td>215,689</td>
<td>–</td>
<td>215,689</td>
<td>429,150</td>
</tr>
<tr>
<td>Travel and other reimbursement</td>
<td>34,327</td>
<td>–</td>
<td>34,327</td>
<td>45,466</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>5,851</td>
<td>–</td>
<td>5,851</td>
<td>5,136</td>
</tr>
<tr>
<td><strong>Total Revenue and Support</strong></td>
<td><strong>965,569</strong></td>
<td><strong>1,003,713</strong></td>
<td><strong>1,969,282</strong></td>
<td><strong>1,996,242</strong></td>
</tr>
</tbody>
</table>

### Net assets released from restrictions
- 2011: $1,180,908
- 2010 (Restated): $(1,180,908)

### TOTAL REVENUE AND SUPPORT
- **Revised**: $2,146,477
- **2010 Total (Restated)**: $(177,195)
- **2011 Total**: $1,969,282
- **2010 Total**: $1,996,242

## EXPENSES

### Program services

<table>
<thead>
<tr>
<th>Project</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>2011 Total</th>
<th>2010 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Project</td>
<td>$ 141,132</td>
<td>–</td>
<td>$ 141,132</td>
<td>$ 255,619</td>
</tr>
<tr>
<td>Cure Project</td>
<td>162,746</td>
<td>–</td>
<td>162,746</td>
<td>–</td>
</tr>
<tr>
<td>Hepatitis and HIV Project</td>
<td>257,057</td>
<td>–</td>
<td>257,057</td>
<td>236,979</td>
</tr>
<tr>
<td>Tuberculosis and HIV Project</td>
<td>843,927</td>
<td>–</td>
<td>843,927</td>
<td>1,484,152</td>
</tr>
<tr>
<td>Communications and Advocacy Project</td>
<td>34,484</td>
<td>–</td>
<td>34,484</td>
<td>12,983</td>
</tr>
<tr>
<td>U.S. and Global Health Policy Project</td>
<td>61,266</td>
<td>–</td>
<td>61,266</td>
<td>12,927</td>
</tr>
<tr>
<td><strong>Total Program Expenses</strong></td>
<td><strong>1,500,612</strong></td>
<td>–</td>
<td><strong>1,500,612</strong></td>
<td><strong>2,002,660</strong></td>
</tr>
</tbody>
</table>

### Management and general
- 2011: $140,076
- 2010: $116,977

### Fundraising
- 2011: $119,042
- 2010: $135,313

### TOTAL SERVICES EXPENSES
- **Revised**: $1,759,730
- **2010 Total (Restated)**: $2,254,950

### Increase (Decrease) in net assets
- 2011: $386,747
- 2010 (Restated): $(177,195)

### Net assets, beginning of year, as originally reported
- 2011: $1,269,459
- 2010: $1,177,008

### Restatement to Reflect Correction of Donated Inventory
- 2011: $1,180,908
- 2010: $(1,180,908)

### Net assets, beginning of year, as restated
- 2011: $2,446,467
- 2010: $2,705,175

### NET ASSETS, END OF YEAR
- **Revised**: $1,656,206
- **2010 Total (Restated)**: $2,656,019
- **2011 Total**: $2,446,467

## Summary of 2011 Functional Expenses

- **Program Services**: 85.28%
- **Management & General**: 7.96%
- **Fundraising**: 6.76%
THE 2011 PALM DONOR CIRCLE
With TAG’s Accelerating Research to Cure AIDS Campaign in Red

The Palm Donor Circle is TAG’s major donor program, named in honor of philanthropist and TAG supporter Michael Palm (1951–1998). Members of the Palm Donor Circle made individual donations of $1,000 or more in 2011.

Benjamin, Christine & Darius Anagnos
Jeanne L. Bergman & Anna Kramarsky
Glen & Debbie Bickerstaff
The Calamus Foundation
David Corkery
Richard A. & Barbara Knowles Debs
Randall G. Drain
Marcus Edward & Ken O’Neill
David France & Jonathan Starch
Howard A. Froman & R. Scott Briggs
M. Lee Garrison
Dr. Michael F. Giordano
Kevin & Neil Goetz
Brian Hargrove & David Hyde Pierce
Judith & Richard Harrington
Barbara F. Hughes & Andrea Benzacar Dailey
Eton John AIDS Foundation
Noel E.D. Kirnon & Michael D. Paley
Michael K. Longacre
Richard M. Lynn & Joseph Evall
Alby P. Maccarone, Jr.
Chrisy & John Mack
Donald B. Marron
Robert J. McClain & Alberto Blanquel
Robert Monteleone

Linda M. & Stuart K. Nelson
Mark O’Donnell & James E. McGreevey
Jason Osher & Richard Schubel
Maria J. Palumbo, Jr. & Stefan Gargiulo
James G. Pepper
Steve Robin
Frank Rappa
Michael L. Rankowitz & Sheila A. Heffron
Walter Rieman
Ron Rose
David Rosenauer & Rex Walker
Jamie Saakvitne & Daniel Chow
Dr. Bruce R. Schackman & Edward K. Sikov
Hon. Walter & Dulcie L. Schackman
Evan Schwartz & Robert Fitterman
Marvin Shulman
Gerald R. & Ellen V. Sigal
Dr. Peter Small & Dr. Delaney Ruston
Monte Steinman
Jan Striker
Elizabeth Taylor AIDS Foundation
W. Kirk Wallace & Mark M. Sexton
P. Forrest Williams
Sally G. Williams
Andrew D. Zacks

UNITED: A group of TAG donors who banded together to commit $5,300 a year for four years for TAG’s Accelerating Research to Cure AIDS Campaign.

Jim Aquino
Michael Beltran & Tim Ford
Bob Bronzo
Karen Bronzo & Jeff Rabb
John Deyling
Jim Edwards
Drew Hodges
Joe Lauretano
David Levine
Robert Monteleone
Greig Sargeant
Sunita Viswanath & Stephan Shaw

TAG BE INVOLVED

Contribute
TAG welcomes donations from individuals who want to see the AIDS research agenda remain responsive to the needs of all people living with HIV.

Make a tax deductible gift now.
www.treatmentactiongroup.org/support

Join TAG’s Board
TAG is always seeking new board members. If you are looking for a great place to invest your time and talents, please call Barbara Hughes, TAG Board President, to learn more. Call 212 253 7922 or Email: barbara.hughes@treatmentactiongroup.org

About TAG
Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS.
TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.
TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.